#高警訊藥品

急性白血病、淋巴肉瘤、何杰金氏病
1. Hodgkin Lymphoma
2. Kaposi sarcoma
3. Langerhans cell histiocytosis
4. Non-Hodgkin lymphomas (Lymphocytic lymphoma, histiocytic lymphoma, advanced mycosis fungoides)
5. Testicular cancer

Antineoplastic Agent, Antimicrotubular:
Vinblastine binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases.

1. Significant granulocytopenia (unless as a result of condition being treated)
2. Presence of bacterial infection

D

Infant risk cannot be ruled out.

Nausea, vomiting, constipation, vesiculations of the mouth, ileus, diarrhea, anorexia, abdominal pain, rectal bleeding, pharyngitis, hemorrhagic enterocolitis bleeding, numbness, parethesias, peripheral neuritis, mental depressions, loss of deep tendon reflexes, headache, convulsions, malaise, weakness, dizziness, pain tumor site, vesiculation of skin.

Dosage:
IV: 3.7 mg/m2; adjust dose every 7 days up to 5.5 mg/m2 (second dose), 7.4 mg/m2 (third dose), 9.25 mg/m2 (fourth dose), 11.1 mg/m2 (fifth dose).
Administration:
1. Dosage adjustment goal is to reduce white blood cell count to ~3,000/mm3.
2. Do not administer more frequently than every 7 days.

No dosage adjustment necessary.

1. Serum bilirubin >3 mg/dL: Administer 50% of dose
2. Serum bilirubin >3 times ULN: Avoid use

D5W or NS with vinblastine 20mg/L is less than 5% vinblastine decomposition in 3 weeks at 4 or 25℃ in the dark.